
FDA approves Abbott's first dual-monitoring glucose and ketone device
The story in brief
The FDA authorized Abbott's Libre Duo 10 Day device, the first to continuously monitor both ketone and glucose levels in diabetes patients. It provides real-time trends and automatic alerts to help detect rising ketones before DKA emergencies. The device, designed for a 10-day wear period for people aged 2 and older, integrates with the Libre app and is expected to work with insulin pumps from Insulet and Tandem in 2027.